Amivantamab is an approved monoclonal antibody that prolongs life by almost two years. The key to this generation of cancer treatments is precision.
Only 40 percent of patients with metastatic lung cancer access these tests, says Diego Kaen, president of the Argentine Association of Clinical Oncology. Molecular testing is part of the diagnosis: just as we perform a tomography and a blood test on the tumor, molecular testing must also be performed on the patient, says Kaen.